Richard O’kennedy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Richard O’kennedy has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Aoife Crawley
School of Biotechnology, Dublin City University, Collins Avenue, Glasnevin, Dublin D09 Y5N0, Ireland
1 shared publication - Bryony L. Hayes
MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom
1 shared publication - Caroline Murphy
School of Biotechnology, , Dublin, Ireland
1 shared publication
Latest Publications
- Open Access
- 2 June 2018
- Published by MDPI AG in Diagnostics
- Vol. 8 (2) , 39
Developments in Point-of-Care Diagnostic Technology for Cancer Detection
Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths.
- 2 June 2018
- Published by MDPI AG in Diagnostics
- Vol. 8 (2) , 39
Open AccessDevelopments in Point-of-Care Diagnostic Technology for Cancer Detection
Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths.